-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
A few days ago, the CDE official website showed that the neostigmine methyl sulfate injection of Chengdu Yuandong Biopharmaceutical was accepted as a 3-type imitation
.
According to the data from Minet.
com, in 2020, the sales of neostigmine injection, a terminal of public medical institutions in China, exceeded 300 million yuan, a year-on-year increase of more than 400%
.
At present, this product has not been reviewed by any company
.
.
According to the data from Minet.
com, in 2020, the sales of neostigmine injection, a terminal of public medical institutions in China, exceeded 300 million yuan, a year-on-year increase of more than 400%
.
At present, this product has not been reviewed by any company
.
Data show that neostigmine methyl sulfate injection is used to reverse the effects of postoperative non-depolarizing neuromuscular blocking agents
.
.
Sales of neostigmine injections in Chinese public medical institutions in recent years (unit: 100 million yuan)
Source: Terminal competition pattern of public medical institutions in China
According to data from Minet.
com, in recent years, the sales of terminal neostigmine injections in China's urban public hospitals, county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) have grown rapidly, exceeding 300 million yuan in 2020, a year-on-year increase.
More than 400%, sales in the first half of 2021 have exceeded the full year of 2020
.
com, in recent years, the sales of terminal neostigmine injections in China's urban public hospitals, county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) have grown rapidly, exceeding 300 million yuan in 2020, a year-on-year increase.
More than 400%, sales in the first half of 2021 have exceeded the full year of 2020
.
Neostigmine injection mainly includes neostigmine methylsulfate injection and neostigmine methylsulfate injection.
Among them, the production enterprises of neostigmine methylsulfate injection are Shanghai Xinyi Jinzhu Pharmaceutical Co.
, Ltd.
and Jiangsu Pujin Pharmaceutical Co.
, Ltd.
Waiting for 4, but no company has reviewed it yet
.
Prior to this, only the supplementary application for consistency evaluation of Shanghai Xinyi Jinzhu Pharmaceutical was under review and approval.
Guangzhou Ruier Medicine | Hebei Kaiwei Pharmaceutical, Chengdu Xinjie High-tech | Taiji Group Sichuan Taiji Pharmaceutical reported as generic 3 categories.
The product is in the review and approval process, and it will be regarded as a review after approval
.
Among them, the production enterprises of neostigmine methylsulfate injection are Shanghai Xinyi Jinzhu Pharmaceutical Co.
, Ltd.
and Jiangsu Pujin Pharmaceutical Co.
, Ltd.
Waiting for 4, but no company has reviewed it yet
.
Prior to this, only the supplementary application for consistency evaluation of Shanghai Xinyi Jinzhu Pharmaceutical was under review and approval.
Guangzhou Ruier Medicine | Hebei Kaiwei Pharmaceutical, Chengdu Xinjie High-tech | Taiji Group Sichuan Taiji Pharmaceutical reported as generic 3 categories.
The product is in the review and approval process, and it will be regarded as a review after approval
.
Source: MED2.
0 China Drug Evaluation Database
0 China Drug Evaluation Database
In 2021, a total of 5 products of Yuandong have been approved for listing, all of which are reported as imitations of Category 4, which are regarded as over-evaluation
.
It covers antithrombotic drugs, systemic antiviral drugs, diabetes drugs and other therapeutic fields (subcategories), among which, repaglinide metformin tablets (II) and repaglinide metformin tablets (I) are the second domestic companies
.
.
It covers antithrombotic drugs, systemic antiviral drugs, diabetes drugs and other therapeutic fields (subcategories), among which, repaglinide metformin tablets (II) and repaglinide metformin tablets (I) are the second domestic companies
.
Source: CDE official website, Minet database
A few days ago, the CDE official website showed that the neostigmine methyl sulfate injection of Chengdu Yuandong Biopharmaceutical was accepted as a 3-type imitation
.
According to the data from Minet.
com, in 2020, the sales of neostigmine injection, a terminal of public medical institutions in China, exceeded 300 million yuan, a year-on-year increase of more than 400%
.
At present, this product has not been reviewed by any company
.
.
According to the data from Minet.
com, in 2020, the sales of neostigmine injection, a terminal of public medical institutions in China, exceeded 300 million yuan, a year-on-year increase of more than 400%
.
At present, this product has not been reviewed by any company
.
Data show that neostigmine methyl sulfate injection is used to reverse the effects of postoperative non-depolarizing neuromuscular blocking agents
.
.
Sales of neostigmine injections in Chinese public medical institutions in recent years (unit: 100 million yuan)
Source: Terminal competition pattern of public medical institutions in China
According to data from Minet.
com, in recent years, the sales of terminal neostigmine injections in China's urban public hospitals, county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) have grown rapidly, exceeding 300 million yuan in 2020, a year-on-year increase.
More than 400%, sales in the first half of 2021 have exceeded the full year of 2020
.
com, in recent years, the sales of terminal neostigmine injections in China's urban public hospitals, county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) have grown rapidly, exceeding 300 million yuan in 2020, a year-on-year increase.
More than 400%, sales in the first half of 2021 have exceeded the full year of 2020
.
Neostigmine injection mainly includes neostigmine methylsulfate injection and neostigmine methylsulfate injection.
Among them, the production enterprises of neostigmine methylsulfate injection are Shanghai Xinyi Jinzhu Pharmaceutical Co.
, Ltd.
and Jiangsu Pujin Pharmaceutical Co.
, Ltd.
Waiting for 4, but no company has reviewed it yet
.
Prior to this, only the supplementary application for consistency evaluation of Shanghai Xinyi Jinzhu Pharmaceutical was under review and approval.
Guangzhou Ruier Medicine | Hebei Kaiwei Pharmaceutical, Chengdu Xinjie High-tech | Taiji Group Sichuan Taiji Pharmaceutical reported as generic 3 categories.
The product is in the review and approval process, and it will be regarded as a review after approval
.
Among them, the production enterprises of neostigmine methylsulfate injection are Shanghai Xinyi Jinzhu Pharmaceutical Co.
, Ltd.
and Jiangsu Pujin Pharmaceutical Co.
, Ltd.
Waiting for 4, but no company has reviewed it yet
.
Prior to this, only the supplementary application for consistency evaluation of Shanghai Xinyi Jinzhu Pharmaceutical was under review and approval.
Guangzhou Ruier Medicine | Hebei Kaiwei Pharmaceutical, Chengdu Xinjie High-tech | Taiji Group Sichuan Taiji Pharmaceutical reported as generic 3 categories.
The product is in the review and approval process, and it will be regarded as a review after approval
.
Source: MED2.
0 China Drug Evaluation Database
0 China Drug Evaluation Database
In 2021, a total of 5 products of Yuandong have been approved for listing, all of which are reported as imitations of Category 4, which are regarded as over-evaluation
.
It covers antithrombotic drugs, systemic antiviral drugs, diabetes drugs and other therapeutic fields (subcategories), among which, repaglinide metformin tablets (II) and repaglinide metformin tablets (I) are the second domestic companies
.
.
It covers antithrombotic drugs, systemic antiviral drugs, diabetes drugs and other therapeutic fields (subcategories), among which, repaglinide metformin tablets (II) and repaglinide metformin tablets (I) are the second domestic companies
.
Source: CDE official website, Minet database
A few days ago, the CDE official website showed that the neostigmine methyl sulfate injection of Chengdu Yuandong Biopharmaceutical was accepted as a 3-type imitation
.
According to the data from Minet.
com, in 2020, the sales of neostigmine injection, a terminal of public medical institutions in China, exceeded 300 million yuan, a year-on-year increase of more than 400%
.
At present, this product has not been reviewed by any company
.
.
According to the data from Minet.
com, in 2020, the sales of neostigmine injection, a terminal of public medical institutions in China, exceeded 300 million yuan, a year-on-year increase of more than 400%
.
At present, this product has not been reviewed by any company
.
Data show that neostigmine methyl sulfate injection is used to reverse the effects of postoperative non-depolarizing neuromuscular blocking agents
.
.
Sales of neostigmine injections in Chinese public medical institutions in recent years (unit: 100 million yuan)
Source: Terminal competition pattern of public medical institutions in China
According to data from Minet.
com, in recent years, the sales of terminal neostigmine injections in China's urban public hospitals, county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) have grown rapidly, exceeding 300 million yuan in 2020, a year-on-year increase.
More than 400%, sales in the first half of 2021 have exceeded the full year of 2020
.
com, in recent years, the sales of terminal neostigmine injections in China's urban public hospitals, county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) have grown rapidly, exceeding 300 million yuan in 2020, a year-on-year increase.
More than 400%, sales in the first half of 2021 have exceeded the full year of 2020
.
Neostigmine injection mainly includes neostigmine methylsulfate injection and neostigmine methylsulfate injection.
Among them, the production enterprises of neostigmine methylsulfate injection are Shanghai Xinyi Jinzhu Pharmaceutical Co.
, Ltd.
and Jiangsu Pujin Pharmaceutical Co.
, Ltd.
Waiting for 4, but no company has reviewed it yet
.
Prior to this, only the supplementary application for consistency evaluation of Shanghai Xinyi Jinzhu Pharmaceutical was under review and approval.
Guangzhou Ruier Medicine | Hebei Kaiwei Pharmaceutical, Chengdu Xinjie High-tech | Taiji Group Sichuan Taiji Pharmaceutical reported as generic 3 categories.
The product is in the review and approval process, and it will be regarded as a review after approval
.
Among them, the production enterprises of neostigmine methylsulfate injection are Shanghai Xinyi Jinzhu Pharmaceutical Co.
, Ltd.
and Jiangsu Pujin Pharmaceutical Co.
, Ltd.
Waiting for 4, but no company has reviewed it yet
.
Prior to this, only the supplementary application for consistency evaluation of Shanghai Xinyi Jinzhu Pharmaceutical was under review and approval.
Guangzhou Ruier Medicine | Hebei Kaiwei Pharmaceutical, Chengdu Xinjie High-tech | Taiji Group Sichuan Taiji Pharmaceutical reported as generic 3 categories.
The product is in the review and approval process, and it will be regarded as a review after approval
.
Source: MED2.
0 China Drug Evaluation Database
0 China Drug Evaluation Database
In 2021, a total of 5 products of Yuandong have been approved for listing, all of which are reported as imitations of Category 4, which are regarded as over-evaluation
.
It covers antithrombotic drugs, systemic antiviral drugs, diabetes drugs and other therapeutic fields (subcategories), among which, repaglinide metformin tablets (II) and repaglinide metformin tablets (I) are the second domestic companies
.
.
It covers antithrombotic drugs, systemic antiviral drugs, diabetes drugs and other therapeutic fields (subcategories), among which, repaglinide metformin tablets (II) and repaglinide metformin tablets (I) are the second domestic companies
.
Source: CDE official website, Minet database
Source: CDE official website, Minet database 
